Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at speedy and cost-effective introduction of efficacious and safe drugs to the market.
The areas of Selvita activity include:
- Research on new chemical entities originating from Polish universities or resulting from Selvita’s own discovery programs,
- Integrated fee-for-service drug discovery projects based on medicinal chemistry, biology and pharmacology services
- Target-based solutions – advanced protein modeling solutions
- drug discovery – custom in-silico library construction
- lead generation – optimization of lead compounds
- contract synthesis and syntheses paths optimization
- information technology for research projects
Selvita is also the majority shareholder of BioCentrum (www.biocentrum.com.pl), which provides preclinical ADMET services, and biopharmaceutical development services.
Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita is involved in several research projects at the pre-clinical stage.
More information http://www.selvita.com/#
Polpharma is the largest manufacturer of drugs and active pharmaceutical ingredients (APIs) in Poland. Polpharma’sproducts are exported to over 50 countries of the world. Polpharma was established in 1935. In 2000 it was privatised with the participation of exclusively Polish capital. Polpharma’s strength is the combination of many years of experience with modern technologies and the highest standards of management.
Polpharma is currently the largest Polish manufacturer of generic drugs and pharmaceutical substances. It produces a wide range of prescription drugs and drugs used in inpatient care. The company specialises in preparations used in cardiology, gastroenterology and neurology. A significant part of Polpharma’s portfolio contains also OTC drugs.
More information http://www.polpharma.pl/en/about-us/
Amgen is the largest independent biotechnology company in the world, that was founded 30 years ago. It employs 17,000 people in 45 countries around the world. 18 million patients take medicines invented and manufactured by Amgen.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines.
- Amgen Poland is an example of successful investment in biotechnology market in Poland
- Nowadays Amgen Poland employs 180 people of which 70% work for the Research and Development – this distinguishes Amgen from other pharmaceutical companies present on the Polish market
- Poland is for Amgen the second largest, after the U.S., country as it regards clinical trials projects
More information www.amgen.pl
Wroclaw Research Centre EIT+, established in 2007, is a unique undertaking in Poland, dedicated to fostering innovation based on the co-operation of academia, local government and innovative business. The company’s shareholders are the largest universities in Wroclaw as well as the authorities of the city of Wroclaw and the region of Lower Silesia.
Apart from physical facilities, the Pracze Campus aims to become a vibrant innovation village, truly supportive of the creative environment indispensable for the development of the Knowledge Based Economy. International colleagues from complementary backgrounds such as business incubators, high technology companies, financial institutions and research will mingle in a collaborative and pleasant atmosphere.
EIT+ is also a founding partner in one of the six European Regional Innovation Communities (RICs) dedicated to address the problem of climate change. It is a newly created undertaking of the European Institute of Innovation and Technology aimed at developing and implementing new life-improving and pro-ecological technologies.
The Company’s most important current initiatives are:
- The Lower Silesia Centre for Materials and Biomaterials – the Pracze Campus
- Biotechnologies and advanced medical technologies – BioMed
- The application of nanotechnology in advanced materials – NanoMat
More information http://www.eitplus.pl/language/en/
Acumen Research Laboratories (ARL) is a contract research organization (CRO) that provides a comprehensive range of customized, high-quality contract R&D services in drug target discovery and pre-clinical drug development to support the pharmaceutical industry and related biomedical sciences research communities world-wide.
The products and services of Acumen Research Laboratories (ARL) can be classified into 7 main categories:
- Project Procedure & Management
- Target Identification, Validation and Enablement
- Biomarker Discovery: Identification and Validation
- Assay Development
- Pre-clinical Drug Development
- Standard Cell and Molecular Biology Work
- Other Services
More information http://www.acumen-research.com
Jagiellonian Centre of Innovation Ltd (JCI) is a business broker for bio partnering and collaboration in Poland. The company promotes also Krakow as a place for R&D Life Science property investments and offers high class laboratory space for lease as well as brokering fee-for-service and contract research with the Jagiellonian University.
JCI manages the first dedicated Life Science Park in Central and Eastern Europe. The JCI offers complex laboratory, analytical and contract research services, property investments and laboratory infrastructure ranging across all life science areas including biotechnology, biotechnics, biomedicine, chemistry, biochemistry, pharmacology, biophysics and physics.
The JCI administers also the Life Science Cluster Krakow & Polish Biotechnology Platform. They are an associations of member companies and organizations, which represents the biggest commercial potential for the biosciences in Poland.
More information http://jci.pl/en/index.php
PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR’s key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.
The LifeScience Klaster Krakow comprise more than 70 private and public entities recruiting from biotech & life science business sector, universities & research institutes, hospital & other health care services, business support organizations and government sector. The idea to form and sustain a commercially viable cluster initiative dedicated to “life sciences” has been developed on understanding and recognition of the already existing potential of both life science industry and research & development sector present in Krakow and the Region. The initiative directly addresses goals included in Regional Innovation Strategy mission statement which aims to increase the level of innovation and competitiveness through stimulating the cooperation of SME’s with a wide range of institutions in the field of science, research& development, and transfer of technologies.
More information http://lifescience.pl/index.php
